SCM
CTNM

Silverarc Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Silverarc Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94M Sell
301,729
-5,811
-2% -$77.9K 0.4% 48
2025
Q4 		$3.52M Buy
307,540
+141,379
+85% +$1.61M 0.49% 47
2025
Q3 		$1.95M Buy
+166,161
New +$1.34M 0.26% 63

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Silverarc Capital Management's CTNM Position: Q1 2026 in Review

Silverarc Capital Management reduced its Contineum Therapeutics (CTNM) stake by 1.9% in Q1 2026, selling an estimated $77.9K and leaving 301,729 shares worth $3.94M. The position accounts for 0.4% of the portfolio, ranked #48.

Silverarc Capital Management first reported a position in CTNM in Q3 2025 and has held it in 3 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Silverarc Capital Management held 301,729 shares of Contineum Therapeutics worth $3.94M as of Q1 2026.
  • Silverarc Capital Management sold 5,811 Contineum Therapeutics shares in Q1 2026, an estimated $77.9K.
  • Contineum Therapeutics made up 0.4% of Silverarc Capital Management's portfolio in Q1 2026, its #48 holding.
  • Silverarc Capital Management first reported a position in Contineum Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.